A5108536457- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Malaria Research and Control
- Advanced Breast Cancer Therapies
- Travel-related health issues
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Mosquito-borne diseases and control
- Global Maternal and Child Health
Institute of Cancer Research
2017
Radboud University Medical Center
2017
Radboud University Nijmegen
2017
The Christie NHS Foundation Trust
2017
Institut Jules Bordet
2017
Beatson West of Scotland Cancer Centre
2017
Université Libre de Bruxelles
2017
Antwerp University Hospital
2017
Synthon (Netherlands)
2017
African Malaria Network Trust
2006
Spatial and longitudinal monitoring of transmission intensity will allow better targeting malaria interventions. In this study, data on meteorological, demographic, entomological parasitological over the course a year was collected to describe epidemiology in single village low intensity.Entomological vectors performed by weekly light trap catches 10 houses. Each house Msitu wa Tembo, Lower Moshi, mapped censused. Malaria cases identified through passive case detection at local health centre...
PURPOSE Human epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies heavily pretreated HER2+/HER2-low cancer. METHODS In...
Abstract Background: SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and cleavable linker-duocarmycin (vc-seco-DUBA) payload. Following proteolytic cleavage the synthetic duocarmycin prodrug activated, binds to minor groove of DNA, subsequently causes irreversible DNA-alkylation. has demonstrated unprecedented anti-tumor activity in preclinical breast cancer models with high (HER2 3+) or moderate/low expression HER2 2+ 1+). Clinical data patients HER2-positive...